Search
Acediasulfone
go.drugbank.com/drugs/DB08926ExperimentalAcediasulfone (INN) is an antimicrobial and antimalarial long-acting prodrug of dapsone.
PPI-2458
go.drugbank.com/drugs/DB05864InvestigationalIn preclinical studies to date, PPI-2458 has demonstrated the potent pharmacologic activity of this class of compounds while displaying an improved pharmacokinetic and toxicity profile. … PPI-2458 is a novel, proprietary molecule belonging to the fumagillin class of compounds that specifically targets the MetAP-2 enzyme.
WIN 55212-2
go.drugbank.com/drugs/DB13950ExperimentalIt is a potent cannabinoid receptor agonist that has been found to be a potent analgesic in a rat model of neuropathic pain. It activates p42 and p44 MAP kinase via receptor-mediated signaling. … WIN 55,212-2 is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of cannabinoids such as tetrahydrocannabinol (THC) but has an entirely different chemical
Categories: Cannabinoid Receptor Antagonists, Receptor, Cannabinoid, CB1, antagonists & inhibitorsNitrofurantoin
go.drugbank.com/drugs/DB00698ApprovedInvestigationalVet approved[A179824] This drug is more resistant to the development of bacterial resistance because it acts on many targets at once. … Nitrofurantoin is a nitrofuran antibiotic used to treat uncomplicated urinary tract infections.
Denifanstat
go.drugbank.com/drugs/DB17576InvestigationalDenifanstat is an orally bioavailable fatty acid synthase (FASN) inhibitor. Due to its antineoplastic activities, it is being investigated for various cancers.
Zilovertamab vedotin
go.drugbank.com/drugs/DB18457InvestigationalZilovertamab vedotin is an Antibody-drug conjugate (ADC) comprising an anti-ROR1 monoclonal antibody (UC-961), a proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker (
Pazopanib
go.drugbank.com/drugs/DB06589ApprovedInvestigationalPazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
NOX-700
go.drugbank.com/drugs/DB05464ExperimentalNOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes). … In animal studies, NOX-700 lowered serum glucose, improved glucose tolerance, and reduced the percentage of total glycated hemoglobin.
Sparsomycin
go.drugbank.com/drugs/DB04222ExperimentalAn antitumor antibiotic produced by Streptomyces sparsogenes. It inhibits protein synthesis in 70S and 80S ribosomal systems. [PubChem]
GC012F
go.drugbank.com/drugs/DB22406InvestigationalGC012F is under investigation in clinical trial NCT06419166 (An Exploratory Clinical Study of GC012F Injection for Refractory gMG).